Cencora, Inc. (NYSE:COR) Shares Purchased by Smithbridge Asset Management Inc. DE

Smithbridge Asset Management Inc. DE raised its holdings in shares of Cencora, Inc. (NYSE:COR) by 85.2% in the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 4,704 shares of the company’s stock after acquiring an additional 2,164 shares during the quarter. Smithbridge Asset Management Inc. DE’s holdings in Cencora were worth $1,059,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds and other institutional investors also recently added to or reduced their stakes in the business. Custom Index Systems LLC purchased a new position in shares of Cencora during the 3rd quarter worth approximately $371,000. J.W. Cole Advisors Inc. lifted its stake in Cencora by 1.3% in the 3rd quarter. J.W. Cole Advisors Inc. now owns 3,669 shares of the company’s stock valued at $826,000 after buying an additional 48 shares in the last quarter. State of Alaska Department of Revenue grew its holdings in Cencora by 6.8% during the 3rd quarter. State of Alaska Department of Revenue now owns 36,252 shares of the company’s stock valued at $8,159,000 after buying an additional 2,295 shares during the last quarter. Valley National Advisers Inc. increased its position in Cencora by 34,181.8% during the third quarter. Valley National Advisers Inc. now owns 7,542 shares of the company’s stock worth $1,697,000 after buying an additional 7,520 shares in the last quarter. Finally, DekaBank Deutsche Girozentrale raised its holdings in shares of Cencora by 0.4% in the third quarter. DekaBank Deutsche Girozentrale now owns 543,013 shares of the company’s stock worth $120,784,000 after acquiring an additional 2,257 shares during the last quarter. Institutional investors and hedge funds own 97.52% of the company’s stock.

Analyst Ratings Changes

A number of analysts recently commented on the company. Evercore ISI decreased their price objective on Cencora from $270.00 to $250.00 and set an “outperform” rating on the stock in a research note on Tuesday, October 8th. Leerink Partners reduced their target price on shares of Cencora from $277.00 to $275.00 and set an “outperform” rating on the stock in a report on Monday, October 7th. Bank of America reiterated a “neutral” rating and set a $245.00 price target (down from $275.00) on shares of Cencora in a report on Wednesday, September 18th. StockNews.com downgraded shares of Cencora from a “strong-buy” rating to a “buy” rating in a research note on Friday, September 20th. Finally, Robert W. Baird decreased their target price on shares of Cencora from $287.00 to $283.00 and set an “outperform” rating on the stock in a research report on Friday, September 6th. Three research analysts have rated the stock with a hold rating and eight have assigned a buy rating to the company’s stock. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average target price of $259.44.

Cencora Trading Down 0.1 %

Cencora stock traded down $0.30 during trading on Monday, reaching $234.17. The company had a trading volume of 38,275 shares, compared to its average volume of 1,404,498. Cencora, Inc. has a 12-month low of $182.75 and a 12-month high of $247.66. The company has a debt-to-equity ratio of 3.93, a quick ratio of 0.55 and a current ratio of 0.89. The stock’s 50 day moving average price is $232.15 and its two-hundred day moving average price is $230.76. The firm has a market capitalization of $46.71 billion, a price-to-earnings ratio of 25.65, a PEG ratio of 1.40 and a beta of 0.44.

Cencora (NYSE:COR) last announced its quarterly earnings data on Wednesday, July 31st. The company reported $3.34 earnings per share (EPS) for the quarter, beating the consensus estimate of $3.18 by $0.16. The company had revenue of $74.20 billion during the quarter, compared to analysts’ expectations of $73.32 billion. Cencora had a net margin of 0.65% and a return on equity of 266.60%. The business’s quarterly revenue was up 10.8% compared to the same quarter last year. During the same period in the previous year, the company earned $2.92 EPS. As a group, equities analysts expect that Cencora, Inc. will post 13.63 earnings per share for the current fiscal year.

Cencora Dividend Announcement

The company also recently disclosed a quarterly dividend, which was paid on Monday, August 26th. Stockholders of record on Friday, August 9th were issued a $0.51 dividend. The ex-dividend date of this dividend was Friday, August 9th. This represents a $2.04 dividend on an annualized basis and a dividend yield of 0.87%. Cencora’s dividend payout ratio (DPR) is 22.32%.

Insider Activity

In related news, major shareholder Walgreens Boots Alliance, Inc. sold 4,438,171 shares of the stock in a transaction that occurred on Thursday, August 1st. The shares were sold at an average price of $240.56, for a total transaction of $1,067,646,415.76. Following the completion of the sale, the insider now owns 19,980,000 shares of the company’s stock, valued at approximately $4,806,388,800. This represents a 0.00 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. In other Cencora news, EVP Silvana Battaglia sold 1,473 shares of the firm’s stock in a transaction dated Tuesday, August 6th. The stock was sold at an average price of $242.69, for a total value of $357,482.37. Following the transaction, the executive vice president now directly owns 10,948 shares of the company’s stock, valued at $2,656,970.12. This trade represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, major shareholder Walgreens Boots Alliance, Inc. sold 4,438,171 shares of the business’s stock in a transaction dated Thursday, August 1st. The stock was sold at an average price of $240.56, for a total value of $1,067,646,415.76. Following the transaction, the insider now owns 19,980,000 shares in the company, valued at approximately $4,806,388,800. This represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 4,461,153 shares of company stock valued at $1,073,075,720 in the last three months. Corporate insiders own 15.80% of the company’s stock.

Cencora Profile

Cencora, Inc sources and distributes pharmaceutical products. The company's U.S. Healthcare Solutions segment distributes pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to various institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and additional services for biotechnology and pharmaceutical manufacturers; pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets; and sales force services to manufacturers.